ArticleAnnals of medicine2026
Serum advanced glycation end-products as a biomarker of cumulative glycaemic burden and complications in type 2 diabetes: a pilot study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced glycation end products (AGEs) link chronic hyperglycaemia to diabetic tissue damage. Serum AGE concentrations across the metabolic disease spectrum, from prediabetes through complicated diabetes, remain incompletely characterized, including the contribution of isolated dyslipidaemia.
objectiveTo quantify serum AGEs across metabolic states and evaluate their biomarker potential for disease staging and complication risk stratification.
methodsCross-sectional study of 226 adults in five groups: healthy controls, isolated hyperlipidaemia, impaired glucose tolerance, uncomplicated type 2 diabetes, and complicated type 2 diabetes. Serum AGEs were measured by ELISA. Group differences were assessed by Kruskal-Wallis tests, logistic regression, and receiver operating characteristic analysis.
resultsSerum AGEs increased progressively across groups (Kruskal-Wallis
conclusionSerum AGEs rise progressively from prediabetes to complicated diabetes, driven by hyperglycaemia. Their discriminative capacity where conventional glycaemic markers plateau supports AGEs as a complementary biomarker for complication risk stratification, pending validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.